- Industry
- 1 min read
Covid-19: Panel for nod to P-2/3 vaccine trials for 2-17-year-olds
The Subject Expert Committee on Covid-19 deliberated on the revised study protocol application given by SII on Tuesday and recommended granting permission to the firm for conducting phase 2/3 trial of Covovax on kids aged 2 to 17 years
NEW DELHI: An expert panel of India’s Central Drug Authority on Tuesday recommended granting permission to Serum Institute of India for conducting phase 2/3 trials of Covid vaccine Covovax on kids aged 2 to 17 years with certain conditions, official sources said. The trials would cover 920 children, 460 each in the age-group of 12-17 and 2-11 across 10 sites.
“The Subject Expert Committee on Covid-19 deliberated on the revised study protocol application given by SII on Tuesday and recommended granting permission to the firm for conducting phase 2/3 trial of Covovax on kids aged 2 to 17 years,” a source said.
“The Subject Expert Committee on Covid-19 deliberated on the revised study protocol application given by SII on Tuesday and recommended granting permission to the firm for conducting phase 2/3 trial of Covovax on kids aged 2 to 17 years,” a source said.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions